Recent 8-K filings for VREX

• May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Varex Q2 revenue $216M (+1% YoY), GAAP EPS -$0.19; guides FY26 rev $860-880M, non-GAAP EPS $0.80-1.00

  Revenue $216M (+1% YoY); Medical $156M, Industrial $60M.

• March 16, 2026, 7:59 PM ET debt materiality 0.75 positive item 1.01item 1.02item 2.03item 8.01item 9.01 ◈ Material Agreements ×3◈ Debt Financings

  Varex closes $490M credit facility, redeems $368M 7.875% notes due 2027

  New facility includes $350M term loan, $100M revolver, $40M delayed draw; matures March 13, 2031.

• February 10, 2026, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Varex Q1 revenue $210M (+5% YoY), Non-GAAP EPS $0.19, guides Q2 rev $210-225M

  GAAP net income $0.05 per diluted share; Non-GAAP EPS $0.19 (up from $0.10 YoY).

• November 18, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Varex Q4 revenue $229M (+11% YoY); Non-GAAP EPS $0.37; guides Q1 $200-215M

  Q4 FY25 revenue $229M, up 11% YoY; Medical segment $152M (+5%), Industrial $77M (+25%).

• August 7, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Varex Q3 revenue $203M beats guidance; GAAP loss $(2.15), non-GAAP profit $0.18

  Revenue of $203M down 3% YoY but above high-end guidance; Industrial segment up 1% to $61M, Medical down 4% to $142M.

• May 8, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Varex Q2 revenue $213M (+3% YoY); China tariff pause cuts Q3 outlook to $180-200M

  GAAP EPS $0.17, Non-GAAP EPS $0.26 vs $0.16 prior year.

• April 4, 2025, 7:59 PM ET regulatory materiality 0.60 negative item 7.01

  China MOFCOM launches anti-dumping probe on CT X-ray tubes; Varex could be impacted

  China MOFCOM announced anti-dumping investigation into medical CT X-ray tubes from US and India.

• February 6, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Varex Q1 FY2025 revenue up 5% YoY to $200M; GAAP net loss $0.01/sh, Non-GAAP EPS $0.07

  Medical segment revenue $145M (+3% YoY); Industrial segment revenue $55M (+10% YoY).

• December 23, 2024, 6:59 PM ET debt materiality 0.75 neutral item 1.01item 1.02item 2.03item 8.01item 9.01

  Varex closes $125M 7.875% senior secured notes due 2027 for convertible note repayment

  $125M aggregate principal at 101.5% of par, 7.875% coupon, maturing 2027.

• December 17, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01item 8.01item 9.01

  Varex prices $125M add'l 7.875% senior secured notes due 2027 to repay convertible notes

  $125M aggregate principal of 7.875% senior secured notes due Oct 2027 priced at 101.5% of par.

• November 19, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Varex Q4 FY24 revenue $206M; GAAP EPS loss $1.22, non-GAAP EPS $0.19

  GAAP net loss of $1.22 per diluted share; non-GAAP EPS of $0.19, down from $0.45 YoY.

• August 1, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Varex Q3 FY2024 revenue down 10% YoY; Q4 guidance weak

  Revenue $209M (-10% YoY); GAAP EPS $0.03, Non-GAAP EPS $0.14 vs $0.37 YoY.

• May 2, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Varex Q2 revenue $206M, down 10% YoY; lowers H2 outlook due to China softness

  Revenue $206M, down 10% YoY; GAAP EPS $0.03, Non-GAAP EPS $0.16 (down from $0.26).

• February 6, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases ×3

  Varex Q1 FY2024 revenue $190M (-8% YoY), GAAP loss $0.01/sh, non-GAAP EPS $0.06

  Revenue $190M, down 8% YoY; Medical segment $140M (-13%), Industrial $50M (+10%).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.65 · Most common event earnings

3 positive 5 negative 13 neutral

source · VREX on sec.gov